Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD : Results from the VERNE study
Bastida Paz, Guillermo (Hospital Universitari i Politècnic La Fe (València))
Marín-Jiménez, Ignacio (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
Forés, Ana (Consorci Hospitalari Provincial de Castelló)
García-Planella, Esther (Institut d'Investigació Biomèdica Sant Pau)
Argüelles-Arias, Federico (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Tagarro, Ignacio (Takeda Farmacéutica España S.A.)
Fernandez-Nistal, Alonso (Takeda Farmacéutica España S.A.)
Montoto, Carmen (Takeda Farmacéutica España S.A.)
Aparicio, Jesús (Takeda Farmacéutica España S.A.)
Aguas, Mariam (Hospital Universitari i Politècnic La Fe (València))
Santos-Fernandez, Javier (Hospital Universitario Río Hortega (Valladolid))
Bosca-Watts, Marta Maia (IBD Unit. Hospital Universitario de Valencia)
Ferreiro-Iglesias, Rocío (Hospital Clínico Universitario (Santiago de Compostela, Galícia))
Merino, Olga (Hospital Universitario de Cruces (Barakaldo, País Basc))
Aldeguer, Xavier (Hospital Universitari de Girona Doctor Josep Trueta)
Cortés Rizo, Xavier (Universidad CEU Cardenal Herrera)
Sicilia Aladrén, Beatriz (Hospital Universitario de Burgos)
Mesonero, Francisco (Hospital Universitario Ramón y Cajal (Madrid))
Barreiro de-Acosta, Manuel (Hospital Clínico Universitario (Santiago de Compostela, Galícia))

Data:	2022
Resum:	Background: Anti-TNFα represent one of the main treatment approaches for the management of inflammatory bowel diseases (IBD). Therefore,the evaluation of their treatment patterns over time provides valuable insights about the clinical value of therapies and associated costs. Aims: To assess the treatment patterns with the first anti-TNFα in IBD. Methods: Retrospective, observational study. Results: 310 IBD patients were analyzed along a 5-year follow-up period. 56. 2% of Crohn's disease (CD) patients started with adalimumab (ADA), while 43. 8% started with infliximab (IFX). 12. 9% of ulcerative colitis (UC) patients initiated with ADA, while 87. 1% initiated with IFX. Treatment intensification was required in 28. 9% of CD and 37. 1% of UC patients. Median time to treatment intensification was shorter in UC than in CD (5. 3 vs. 14. 3 months; p = 0. 028). Treatment discontinuation due to reasons other than remission were observed in 40. 7% of CD and 40. 5% of UC patients, although, in UC patients there was a trend to lower discontinuation rates with IFX (36. 6%) than with ADA (66. 7%). Loss of response accounted for approximately one-third of discontinuations, in both CD and UC. Conclusions: Around one-third of IBD biologic-naive patients treated with an anti-TNFα required treatment intensification (earlier in UC) and around 40% discontinued the anti-TNFα due to inappropriate disease control.
Nota:	Altres ajuts: Takeda Farmacéutica España S.A.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Anti-TNFα ; Inflammatory bowel disease ; Treatment discontinuation ; Treatment intensification
Publicat a:	Digestive and Liver Disease, Vol. 54 Núm. 1 (january 2022) , p. 76-83, ISSN 1878-3562

DOI: 10.1016/j.dld.2021.06.005
PMID: 34244110

8 p, 696.4 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats